{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-004321","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2024-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.054983+00:00","generated_at":"2026-06-06T15:59:07.263547+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunocore reports preliminary 2023 KIMMTRAK revenue of $235M, announces $300M convertible notes offering","bullets":["Q4 2023 KIMMTRAK net sales ~$66M; full-year 2023 net sales ~$235M.","Cash and equivalents at Dec 31, 2023 ~$443M.","Proposed $300M convertible senior notes due 2030; initial purchasers option for additional $45M.","Net proceeds to accelerate clinical pipeline, expand commercial, and repay Pharmakon loans.","Pipeline: tebentafusp Phase 2/3 cutaneous melanoma topline data expected Q4 2024; IMC-F106C Phase 3 first-line melanoma trial first patient randomization Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-004321","json":"https://secwatch.observer/filing/0001140361-24-004321.json","markdown":"https://secwatch.observer/filing/0001140361-24-004321.md","text":"https://secwatch.observer/filing/0001140361-24-004321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124004321/0001140361-24-004321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124004321/ef20020073_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T15:59:07.263547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1bda4351e414443a837fe027e35d451ba1ca186c","claim":"Immunocore Holdings plc reported the fourth quarter of 2023 and the full year 2023 results: revenue approximately $66 million.","evidence_excerpt":"Immunocore Holdings plc (the “Company”) expects to report preliminary unaudited net product revenue (“net sales”) arising from the sales of KIMMTRAK (tebentafusp) of approximately $66 million for the fourth quarter of 2023 and approximately $235 million for the full year 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124004321/0001140361-24-004321-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023 and the full year 2023"},{"label":"Revenue","value":"approximately $66 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}